chronic insomnia

The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.

Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces.